FDA Should Be Allowed To Schedule Foreign Inspections Based On Risk – CDER’s Woodcock

Potential legislation to strengthen FDA oversight of foreign drug producers should allow the agency to target facilities and products based on risk, Center for Drug Research and Evaluation Director Janet Woodcock recommended at a May 1 House Energy and Commerce Health Subcommittee hearing